| Literature DB >> 12634474 |
Jürgen Deckert1, Markus Brenner, Nuria Durany, Robert Zöchling, Werner Paulus, Gerhard Ransmayr, Thomas Tatschner, Walter Danielczyk, Kurt Jellinger, Peter Riederer.
Abstract
Adenosine A (2A) receptors have been implicated in the pathophysiology of schizophrenia by clinical, anatomical, biochemical and genetic studies. We hypothesized that a genetically determined low number of adenosine A (2A) receptors could be a vulnerability factor for the development of the disease. The density of adenosine A (2A) receptors was investigated in human postmortem striatum of patients with schizophrenia (n = 9) and matched controls ( n= 9) using [ H)CGS 21680 as a radioligand probe. The maximum number of binding sites (B) (max) was 70% higher in patients with schizophrenia than in matched controls (609.4 +/- 259.1 354.0 +/- 156.4 fmol/mg protein, p=0.04). No significant difference could be discerned for the affinity of caffeine for adenosine A receptors between patients and controls. The increase in receptor density correlated with the dose of antipsychotic medication in chlorpromazine equivalents (r =0.61, = 0.014). We failed to provide evidence for a genetically determined reduction of adenosine A 2(A) receptors in schizophrenia. Instead, consistent with findings from animal experiments, our observation supports a role of adenosine A (2A) receptors in the molecular effects of antipsychotic drugs.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12634474 DOI: 10.1097/00001756-200303030-00003
Source DB: PubMed Journal: Neuroreport ISSN: 0959-4965 Impact factor: 1.837